Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Department of Statistical Science, Duke University, Durham, NC, United States of America.
PLoS One. 2020 Feb 26;15(2):e0229497. doi: 10.1371/journal.pone.0229497. eCollection 2020.
Previous studies have demonstrated that opioids are often prescribed and associated with complications in outpatients with cirrhosis. Less is known about opioids among hospitalized patients with cirrhosis. We aimed to describe the patterns and complications of opioid use among inpatients with cirrhosis.
This retrospective cohort study included adult patients with cirrhosis admitted to a single hospital system from 4/4/2014 to 9/30/2015. We excluded hospitalizations with a surgery, invasive procedure, or palliative care/hospice consult in order to understand opioid use that may be avoidable. We determined the frequency, dosage, and type of opioids given during hospitalization. Using bivariable and multivariable analyses, we assessed length of stay, intensive care unit transfer, and in-hospital mortality by opioid use.
Of 217 inpatients with cirrhosis, 118 (54.4%) received opioids during hospitalization, including 41.7% of patients without prior outpatient opioid prescriptions. Benzodiazepines or hypnotic sleep aids were given to 28.8% of opioid recipients. In the multivariable model, younger age and outpatient opioid prescription were associated with inpatient opioids. Hospitalization was longer among opioid recipients (median 3.9 vs 3.0 days, p = 0.002) and this difference remained after adjusting for age, cirrhosis severity, and medical comorbidities. There was no difference in intensive care unit transfers and no deaths occurred. At discharge, 22 patients were newly started on opioids of whom 10 (45.5%) had opioid prescriptions at 90 days post-discharge.
In non-surgical inpatients with cirrhosis, opioid prescribing was common and associated with prolonged length of stay. A high proportion of patients newly discharged with opioid prescriptions had ongoing prescriptions at 90 days post-discharge.
先前的研究表明,在门诊肝硬化患者中,阿片类药物经常被开具处方,并与并发症相关。关于住院肝硬化患者的阿片类药物使用情况知之甚少。我们旨在描述住院肝硬化患者使用阿片类药物的模式和并发症。
本回顾性队列研究纳入了 2014 年 4 月 4 日至 2015 年 9 月 30 日期间在单一医院系统住院的成年肝硬化患者。我们排除了手术、有创操作或姑息治疗/临终关怀咨询的住院患者,以了解可能可避免的阿片类药物使用情况。我们确定了住院期间给予的阿片类药物的频率、剂量和类型。通过单变量和多变量分析,我们评估了阿片类药物使用与住院时间、重症监护病房转科和院内死亡率之间的关系。
在 217 例肝硬化住院患者中,有 118 例(54.4%)在住院期间使用了阿片类药物,其中 41.7%的患者没有门诊阿片类药物处方。28.8%的阿片类药物使用者同时使用了苯二氮䓬类药物或催眠助眠药物。在多变量模型中,年龄较小和门诊阿片类药物处方与住院阿片类药物的使用相关。阿片类药物使用者的住院时间更长(中位数 3.9 天 vs 3.0 天,p=0.002),并且在调整年龄、肝硬化严重程度和合并症后,这种差异仍然存在。两组在重症监护病房转科率方面没有差异,也没有死亡病例发生。出院时,有 22 例患者开始新使用阿片类药物,其中 10 例(45.5%)在出院后 90 天内有阿片类药物处方。
在非手术住院肝硬化患者中,阿片类药物的开具较为常见,且与住院时间延长相关。很大一部分新出院的患者在出院后 90 天内仍有阿片类药物处方。